Citadel Advisors
ABMD

Citadel Advisors’s Abiomed Inc ABMD Stock Holding History

Citadel Advisors’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,005
Closed -$493K – 15829
2022
Q3 		$493K Sell
2,005
-110,825
-98% -$29.9M ﹤0.01% 8486
2022
Q2 		$27.9M Buy
112,830
+106,518
+1,688% +$28.7M 0.01% 1523
2022
Q1 		$2.09M Buy
+6,312
New +$1.94M ﹤0.01% 5999
2021
Q4 		– Sell
-13,601
Closed -$4.6M – 15238
2021
Q3 		$4.43M Sell
13,601
-33,136
-71% -$11.2M ﹤0.01% 4543
2021
Q2 		$14.6M Sell
46,737
-39,980
-46% -$12.3M ﹤0.01% 2513
2021
Q1 		$27.6M Buy
86,717
+46,225
+114% +$14.8M 0.01% 1600
2020
Q4 		$13.1M Buy
40,492
+37,647
+1,323% +$10.4M ﹤0.01% 2295
2020
Q3 		$788K Sell
2,845
-29,877
-91% -$8.61M ﹤0.01% 6461
2020
Q2 		$7.9M Buy
+32,722
New +$6.57M ﹤0.01% 2499
2020
Q1 		– Sell
-64,739
Closed -$10.7M – 10408
2019
Q4 		$11M Buy
+64,739
New +$12M ﹤0.01% 2093
2019
Q3 		– Sell
-66,687
Closed -$14.4M – 9954
2019
Q2 		$17.4M Sell
66,687
-110,823
-62% -$29.4M 0.01% 1565
2019
Q1 		$50.7M Buy
177,510
+175,370
+8,195% +$58.3M 0.03% 685
2018
Q4 		$696K Sell
2,140
-174,916
-99% -$60.8M ﹤0.01% 5887
2018
Q3 		$79.6M Buy
177,056
+129,959
+276% +$51.2M 0.04% 512
2018
Q2 		$19.3M Buy
47,097
+30,669
+187% +$11.1M 0.01% 1348
2018
Q1 		$4.78M Buy
16,428
+3,264
+25% +$827K ﹤0.01% 2507
2017
Q4 		$2.47M Buy
13,164
+10,832
+464% +$2.02M ﹤0.01% 3341
2017
Q3 		$393K Buy
+2,332
New +$353K ﹤0.01% 5656
2017
Q2 		– Sell
-79,291
Closed -$10.7M – 8260
2017
Q1 		$9.93M Sell
79,291
-15,528
-16% -$1.8M 0.01% 1446
2016
Q4 		$10.7M Buy
94,819
+51,678
+120% +$5.99M 0.01% 1305
2016
Q3 		$5.55M Buy
43,141
+2,741
+7% +$328K 0.01% 1872
2016
Q2 		$4.42M Sell
40,400
-63,278
-61% -$6.3M ﹤0.01% 1926
2016
Q1 		$9.83M Buy
103,678
+93,744
+944% +$7.91M 0.01% 1204
2015
Q4 		$897K Sell
9,934
-190,610
-95% -$16.2M ﹤0.01% 3711
2015
Q3 		$18.6M Buy
200,544
+129,317
+182% +$11.4M 0.02% 958
2015
Q2 		$4.68M Buy
71,227
+46,493
+188% +$3.09M ﹤0.01% 2129
2015
Q1 		$1.77M Sell
24,734
-50,181
-67% -$2.72M ﹤0.01% 3218
2014
Q4 		$2.85M Buy
+74,915
New +$2.36M ﹤0.01% 2536
2014
Q3 		– Sell
-47,372
Closed -$1.19M – 8510
2014
Q2 		$1.19M Buy
47,372
+44,398
+1,493% +$1.03M ﹤0.01% 3278
2014
Q1 		$77K Buy
2,974
+2,964
+29,640% +$82K ﹤0.01% 6416
2013
Q4 		$0 Sell
10
-18,906
-100% -$467K ﹤0.01% 7220
2013
Q3 		$361K Sell
18,916
-90,740
-83% -$2.07M ﹤0.01% 4156
2013
Q2 		$2.36M Buy
+109,656
New +$2.2M ﹤0.01% 2336

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's ABMD Position: Q4 2022 in Review

Citadel Advisors sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 2,005 shares — an estimated $493K sold.

Citadel Advisors first reported a position in ABMD in Q2 2013 and held it in 33 quarters. The position peaked at $79.6M in Q3 2018. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Citadel Advisors reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Citadel Advisors sold 2,005 Abiomed Inc shares in Q4 2022, an estimated $493K.
  • Citadel Advisors first reported a position in Abiomed Inc in Q2 2013 and held it in 33 quarters.
  • Citadel Advisors's Abiomed Inc position peaked at $79.6M in Q3 2018.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.